ClinicalTrials.gg
RecruitingNCT06898749MCP-EpiUpdated Oct 6, 2026

Impact of Canine Mediation Practice in Psychomotor Therapy on Improving the Quality of Life in Adult Epileptic Patients.

An interventional study of canine mediation and standard psychomotor therapy in Epilepsy, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 6, 2026Now RecruitingFirst site in France+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild — 7 open to participants now, 7 under way, none of them phase 3. Epilepsy · Fondation Ophtalmologique Adolphe de Rothschild.

Started
2026
the only one that year
No phase
3 of 10
2 open now
Registered
7th of 10
by date

Among the 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild, this one is the only one that started in 2026, is one of 3 with no phase, and was the 7th registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

7 of the 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild, or all of them as a file.
02

Study summary

In addition to the search for new pharmaceutical or surgical solutions that could improve the therapeutic management of epileptic individuals, it is interesting to ask whether other complementary approaches, such as canine mediation in psychomotor therapy, could enhance the quality of life in this population.

However, there is currently no evidence indicating that exposure to animals through mediation sessions would be beneficial for epileptic individuals, particularly regarding their quality of life, anxiety, emotional management, or cognition (such as social cognition). In the absence of current data in this population, it seems pertinent to study the impact of this practice on people with epilepsy. Furthermore, beyond quality of life, it would be valuable to examine whether it also influences anxiety or the frequency of seizures in individuals with epilepsy (a phenomenon reported for epileptic individuals living with a pet dog or a service dog). Canine mediation could help better manage and regulate the emotions of epileptic individuals, as well as improve their self-esteem.

03

Conditions studied

  • Epilepsy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Person aged ≥ 18 years
  • Presenting pharmacoresistant epilepsy according to the criteria of the International League Against Epilepsy
  • Requiring psychomotor therapy sessions for one of the following indications:

Difficult emotional and relational management And/or global motor difficulties And/or body schema organization disorder And/or temporo-spatial disorder

  • Explicit consent or no opposition to participation in the study by the patient and/or their legal representative or guardian
  • Image rights consented by the patient and their legal representative or guardian, if applicable
  • Hospitalization or residence at the Teppe Institute or at the FAM (Foyer d'Accueil Médicalisé) des 4 Jardins planned for at least 3 months
  • Affiliated with or a beneficiary of a social security scheme

Exclusion criteria

Exclusion Criteria:

  • Fear or phobia of dogs
  • Epileptic person benefiting from a legal protection measure other than guardianship or curatorship
  • Person with insufficient cognitive abilities to respond to the questionnaires
  • Pregnant or breastfeeding woman
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    canine mediation in psychomotor therapy

    Group psychomotor therapy sessions combined with canine mediation (1 session per week for 10 weeks)

    Other: canine mediation

  • Active comparator
    standard psychomotor therapy

    Standard group psychomotor therapy sessions (1 session per week for 10 weeks)

    Other: standard psychomotor therapy

Interventions

  • Othercanine mediation

    Animal mediation consists of bringing an animal into contact with a specific audience to improve the mental or physical health of a person. The dog and beneficiaries interact through various activities, in which the animal participates, offered during the sessions. The dog plays a particularly important role as a mediator through the bonds it forms with the human, as well as a non-judgmental partner in interaction. The canine educator will be accompanied by a healthcare professional during interventions. The sessions are organized based on the expertise and suggestions of both professions (canine educator and psychomotor therapist). The canine educator will be a state-certified professional educator with a specialization in animal mediation. The dog used is trained by the educator, with two types of learning being worked on: emotions and "commands" on cue.

  • Otherstandard psychomotor therapy

    standard sessions of psychomotor therapy

06

What researchers measure

Primary outcomes

  1. Improvement of quality of life

    Increase in the Quality of Life in Epilepsy Inventory-31 (QOLIE-31) score of at least 5 points between inclusion and one week after the completion of the 10 sessions. The score of the QOLIE-31 (Quality of Life in Epilepsy Inventory-31) ranges from 0 to 100. A score of 0 represents the worst possible quality of life, while a score of 100 represents the best possible quality of life.

    Time frame: Day 0 and Day 7 after the end of the 10 sessions

07

Study locations

1 of 2 sites recruiting
  • Fondation Partage et Vie - FAM Les Quatre Jardins
    Saint-Étienne-de-Saint-Geoirs, 38590, France
    Not yet recruiting
  • Institut La Teppe
    Tain-l'Hermitage, 26600, France
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Mar 2030, 42 months after the start.

Of 339 non-industry interventional studies with no phase under Epilepsy, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 77. This study's planned 42 months is close to that.

Counting every sponsor, half of 360 studies reached it within 42 months; a quarter within 19 and three quarters within 77.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: start Jan 2026 → Sep 2026, primary completion Jun 2029 → Mar 2030 and completion Jun 2029 → Mar 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2025
First posted
Mar 27, 2025
StartActual
Sep 14, 2026was Jan 2026
Primary completionEst.
Mar 2030was Jun 2029
CompletionEst.
Mar 2030was Jun 2029
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 6, 2026
Sites
2 sites added — first site in France
Show 2 added (2 France)
  • Fondation Partage et Vie - FAM Les Quatre Jardins · Saint-Étienne-de-Saint-Geoirs, France
  • Institut La Teppe · Tain-l'Hermitage, France
Oct 6, 2026
Start date
Jan 2026→Sep 14, 2026 (actual)
Oct 6, 2026
Primary completion
Jun 2029→Mar 2030
Oct 6, 2026
Study completion
Jun 2029→Mar 2030
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in France
    Show 2 added (2 France)
    • Fondation Partage et Vie - FAM Les Quatre Jardins · Saint-Étienne-de-Saint-Geoirs, France
    • Institut La Teppe · Tain-l'Hermitage, France
    Start date Jan 2026→Sep 14, 2026 (now actual)
    Primary completion Jun 2029→Mar 2030
    Study completion Jun 2029→Mar 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06898749
Responsible party
Sponsor
First posted
Mar 27, 2025
Start date
Sep 14, 2026
Primary completion
Mar 2030 (estimated)
Completion
Mar 2030 (estimated)
Last update
Oct 6, 2026

Study contacts

Amelie Yavchitz
Contact
ayavchitz@for.paris
+33148036454

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion